NCT07730723RecruitingPhase 2/3
The Effect of Nicorandil on Rheumatoid Arthritis Patients
The Effect of Nicorandil on Disease Activity in Rheumatoid Arthritis Patients
Source: ClinicalTrials.gov · Last updated 16 Sept 2026
Brief summary (registry, in English)
The aim of this clinical trial is to determine whether nicorandil works in minimizing disease severity in patients with rheumatoid arthritis. The study will also assess the safety and tolerability of nicorandil. The main questions it aims to answer are: * Could nicorandil improve disease severity and symptoms of rheumatoid arthritis? * Does nicorandil lower the number of times participants need to use pain relieve medications? * Does the nicorandil improve participants functionality and ability to carry out daily activity? * Does nicorandil correct disease-associated damage and inflammation? * What side effects do participants have when taking nicorandil? Researchers will compare nicorandil to a placebo (a look-alike substance that contains no drug) to see if nicorandil works to decrease symptoms and severity of rheumatoid arthritis. Participants will: * Take nicorandil or a placebo two times daily for 3 months * Visit the clinic once every month for checkups * Keep a diary of their symptoms and the number of times they use a pain reliever
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 23 Jul 2026
- Start date
- 6 Sept 2026
- Primary completion date
- Jul 2027
- Lead sponsor
- Ain Shams University
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07730723
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 70
- From 6 Sept 2026 to the primary completion date, Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving bDMARDs or tsDMARDs.
- Use of drugs contraindicated with nicorandil (e.g., sildenafil, tadalafil, vardenafil, tricyclic antidepressants, or guanyl cyclase).
Other illness
- Other autoimmune diseases
- Malignancy or history of malignancy
- Hypersensitivity to nicorandil.
- Left ventricular heart failure or severe hypotension (SBP ˂100 mmHg).
- History of cardiogenic shock.
- History or active gastric ulcer.
Other
- Poor patient compliance
- Pregnancy or lactation.
Who the study is looking for
- Adult (≥18 years).
- Confirmed diagnosis with RA according to ACR/EULAR 2010 criteria.
- Moderate to severe disease activity (DAS-28 ˃ 3.2).
- Stable on conventional treatment for at least 3 months.
- Adequate kidney and liver function.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ain Shams University Hospitals Coordinator of this site? Confirm its status | Cairo | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.